Gene & Cell Therapy vs FDA Actions
Side-by-side coverage analysis for Gene & Cell Therapy and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Gene & Cell Therapy
CRISPR, CAR-T, gene editing
- Stories
- 12
- Avg Impact
- 6.8/10
- Dominant Tone
- Neutral
- Latest
- Jul 12, 2026
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 20
- Avg Impact
- 7/10
- Dominant Tone
- Bullish
- Latest
- 2d ago
Recent Headlines
Gene & Cell Therapy
- UniQure Jumps 78% as FDA Accepts Phase 1/2 Data for AMT-130 BLA
- Casgevy Wins FDA Nod for Kids 2+, Widening $2.2M Gene Therapy Duel
- REGENXBIO CMO Sells $688K Shares After Q1 Miss, Yet Analysts See 99% Upside
- Ocular's $51.8M Revenue at -513% Margin vs. Prime's Gene-Editing Moonshot
- Rocket Pharmaceuticals Shares Slide 4.4% Amid Regulatory and Financing Shifts
- REGENXBIO Q4 Earnings Miss Highlights Gene Therapy Sector Volatility
- Colossal Biosciences Faces Ethical Scrutiny Over Mammoth De-Extinction Goals
- uniQure Eyes 2029 Runway as FDA Talks for Huntington's Gene Therapy Continue
- B.C. Man Cured of Rare Disease in Landmark CRISPR Gene-Editing Success
- B.C. Teen Becomes First in World Cured of Rare Disease via Gene Editing
FDA Actions
- Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
- Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
- Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says
- Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void
- Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
- HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
- AIIMS Recruits 460+ Researchers, Supercharging India’s Biomedical Pipeline
- First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status
- Roundup Ruling: 7-2 SCOTUS Verdict Reduces Bayer's Liability by Billions
- $6.5B Fraud Sweep Nabs Genetic Testing Scams: Biotech’s Compliance Wake-Up Call